Latus Bio
PrivateLast Round
Series A
May 4, 2026
Total Funding Raised
$194M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Latus Bio is a biotechnology company that develops precision gene therapies for central nervous system and peripheral diseases using proprietary AAV capsid engineering and computational discovery platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Latus Bio Comparables
Compare Latus Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Capsida Biotherapeutics | 84% | |
| Capsigen | 84% | |
| Apertura Gene Therapy | 84% |
Latus Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 4, 2026 | ||||
| Series A | May 2, 2024 |
Latus Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Helen's Pink Sky Foundation | Series A |
| Benjamin Franklin Technology Partners | Series A |
| DCVC Bio | Series A |
| Gaingels | Series A |
| Korea Development Bank | Series A |
| BioAdvance Capital | Series A |
| 8VC | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 4, 2026
$97M round led by 8VC and DCVC Bio.
- Nov 3, 2025
Launched an AI/ML strategy for AAV gene therapy and added two scientific advisors.
Recent news
Latest coverage and updates
- hiresSep 10, 2026
Latus Bio, Inc. hired Donald Hayden as Chairman of the Board on Sep 9th '26.
- hiresSep 9, 2026
Latus Bio, Inc. hired Michael MacLean as Independent Director and Chair of the Audit Committee on Sep 9th '26.
- hiresSep 9, 2026
Latus Bio, Inc. hired Don as Chairman of the Latus Board of Directors on Sep 9th '26.
Latus Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Latus Bio's valuation, stock price, and market status.
Is Latus a public or private company?
Latus is a private company.
What is the current stock price of Latus?
Latus is a private company with no public stock price. No recent secondary market data is available.
How much is Latus worth (valuation)?
Valuation information for Latus is not publicly available.
Can I buy Latus stock?
Latus shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Latus's last funding round?
Latus's most recent funding round was Series A Extension on May 4, 2026.
Who are the main investors in Latus?
Key investors in Latus include DCVC Bio, 8VC, DCVC (Data Collective).
Will Latus IPO soon?
No public IPO plans have been announced for Latus.
How can I track Latus secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Latus's secondary market activity and sign up for updates.